Targeted Disease(s):
COPD
Purpose of Study:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Study Dates:
March 25, 2025 - June 5, 2029
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide|WA
Lead Institution:
Western Washington Medical Group
Sponsors:
AstraZeneca
Contact:
Samantha McCurdy
425-225-2780
smccurdy@wwmedgroup.com
ClinicalTrails.gov Identifier:
NCT06878261
